Status:
COMPLETED
Multiple Ascending Dose Study of BMS-582949 in Patients With Stable Rheumatoid Arthritis on the Methotrexate Background
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
The purpose of this clinical research study is to learn if it is safe for rheumatoid arthritis patients to take BMS-582949 along with methotrexate.
Eligibility Criteria
Inclusion
- Age 18-70 years
- Diagnosis of RA for ≥6 months
- Swollen or tender joint or ESR \>ULN. Subject must be on stable doses of MTX
- Women of Childbearing Potential
Exclusion
- Serum transaminase levels \>ULN
- CK\>ULN
- Cannot have taken Orencia or Remicade within 8 weeks of baseline, Humira or Enbrel within 4 weeks of baseline
- Use of H2 blockers or Proton Pump inhibitors while on study
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2007
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT00162292
Start Date
November 1 2005
End Date
October 1 2007
Last Update
March 2 2010
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Desert Medical Advances
Palm Desert, California, United States, 92260
2
Boling Clinical Trials
Upland, California, United States, 91786
3
Delray Research Associates
Delray Beach, Florida, United States, 33484
4
Ocala Rheumatology Research Center
Ocala, Florida, United States, 34474